DRD2 and acute myeloid leukemia: Additionally, thioridazine and other DRD2 antagonists could be modified to improve tolerability, as dose-limiting toxicities such as cardiac arrhythmias and neurologic events have been reported in patients given thioridazine for AML treatment [70].